Athersys (ATHX) Reports Q2, Provides Updates
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/12/2026
- US stocks close down as oil spikes 12%, job market weakens
- U.S. nonfarm payroll employment unexpectedly falls in February
- Oracle stock falls on report of scrapped Texas data center plans
- Kuwait cuts oil output as storage fills up
- Boeing reportedly nearing 500-aircraft deal with China ahead of Trump visit
- After-hours movers: Marvell, Samsara, GAP, Cooper Cos.
- After-hours movers: Broadcom, StubHub, Cracker Barrel, Grocery Outlet, Veeva Systems and more
- After-hours movers: Moderna, CrowdStrike, Ross Stores, Box and more
- After-hours movers: MongoDB, Credo, SoFi Technologies and more
- After-hours movers: Dell, Block, CoreWeave, Autodesk, MARA and more
Athersys Reports Second Quarter 2023 Financial Results and Business Highlights
August 16, 2023 5:01 PM UTCCLEVELAND--(BUSINESS WIRE)-- Athersys, Inc. (Nasdaq: ATHX), a regenerative medicine company developing MultiStem® (invimestrocel) cell therapy for critical care indications, announced financial results for the three and six months ended June 30, 2023 and provided a business update.
Second Quarter 2023 and Recent Corporate and Operational Highlights:
Nominated healthcare executive and strategy consultant Neema Mayhugh, Ph.D. to the Companys Board of Directors Surpassed two-thirds patient enrollment in the MASTERS-2 clinical trial with MultiStem for ischemic stroke Completed Memorandum of Understanding with Healios to provide... More